N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer

Pan,Shengli; Deng,Yingying; Fu,Jun; Zhang,Yuhao; Zhang,Zhijin; Qin,Xianju

doi:10.3892/ijo.2022.5304

N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer

Authors:
- Shengli Pan
- Yingying Deng
- Jun Fu
- Yuhao Zhang
- Zhijin Zhang
- Xianju Qin
View Affiliations

Affiliations: Division of Gastrointestinal Surgery, Department of General Surgery, Shanghai Eighth People Hospital, Jiangsu University, Shanghai 200232, P.R. China, Department of Ophthalmology, Shanghai Eighth People Hospital, Jiangsu University, Shanghai 200232, P.R. China
Published online on: January 7, 2022 https://doi.org/10.3892/ijo.2022.5304
Article Number: 14
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to 5‑Fluorouracil (5‑FU) is a frequent occurrence in patients with colorectal cancer (CRC). MicroRNAs (miRNAs) from cancer‑associated fibroblasts (CAFs)‑secreted exosomes have been associated with 5‑FU sensitivity. The potential molecular mechanism of CAFs‑exosomal miRNAs in CRC remains unclear. The aim of the present study was to elucidate the role of exosomal miRNAs in 5‑FU sensitivity in CRC. Exosomes derived from CAFs were extracted. Exosomal miR‑181d‑5p was identified as a miRNA associated with 5‑FU sensitivity. The putative function of exosomal miR‑181d‑5p was evaluated by ethynyl‑2‑deoxyuridine staining, flow cytometry, RNA immunoprecipitation, luciferase reporter assay, tumor xenograft formation, reverse transcription‑quantitative PCR and western blot analysis. Modification of miR‑181d‑5p by the RNA N6‑methyladenosine (m⁶A) methyltransferase like (METTL)3 was examined by m6A methylation analysis. The results indicated that m⁶A modification and METTL3 expression were upregulated in CRC patients. METTL3‑dependent m⁶A methylation promoted the miR‑181b‑5p process by DiGeorge Syndrome Critical Region 8 (DGCR8) in CAFs. CAFs‑derived exosomes inhibited 5‑FU sensitivity in CRC cells through the METTL3/miR‑181d‑5p axis. A mechanistic study revealed that miR‑181d‑5p directly targeted neurocalcin δ (NCALD) to inhibit the 5‑FU sensitivity of CRC cells. Patients with higher NCALD levels exhibited a higher survival rate. Taken together, METTL3‑dependent m⁶A methylation was upregulated in CRC to promote the processing of miR‑181d‑5p by DGCR8. This led to increased miR‑181d‑5p expression, which inhibited the 5‑FU sensitivity of CRC cells by targeting NCALD. The results of the present study provided novel insight into exosomal microRNAs in 5‑FU sensitivity in CRC cells. Furthermore, exosomal miR‑181d‑5p may represent a potential prognostic marker for CRC.

View Figures

View References

1	Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO and Nielsen DL: Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treat Rev. 62:61–73. 2018. View Article : Google Scholar
2	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019. View Article : Google Scholar : PubMed/NCBI
3	Provenzale D and Gray RN: Colorectal cancer screening and treatment: Review of outcomes research. J Natl Cancer Inst Monogr. 45–55. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jullumstrø E, Lydersen S, Møller B, Dahl O and Edna TH: Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. Eur J Cancer. 45:2383–2390. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tsikitis VL, Larson DW, Huebner M, Lohse CM and Thompson PA: Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 14:3362014. View Article : Google Scholar : PubMed/NCBI
6	Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 25:2198–2204. 2007. View Article : Google Scholar : PubMed/NCBI
7	Benson AB III, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, et al: Metastatic colon cancer, version 3.2013: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 11:141–152. 2013. View Article : Google Scholar : PubMed/NCBI
8	Xu F, Ye ML, Zhang YP, Li WJ, Li MT, Wang HZ, Qiu X, Xu Y, Yin JW, Hu Q, et al: MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Cancer Sci. 111:1528–1541. 2020. View Article : Google Scholar : PubMed/NCBI
9	Liu T, Han C, Wang S, Fang P, Ma Z, Xu L and Yin R: Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy. J Hematol Oncol. 12:862019. View Article : Google Scholar : PubMed/NCBI
10	Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ziani L, Chouaib S and Thiery J: Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 9:4142018. View Article : Google Scholar : PubMed/NCBI
12	Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, et al: Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 24:1277–1289. 2018. View Article : Google Scholar : PubMed/NCBI
13	Keller F, Bruch R, Schneider R, Meier-Hubberten J, Hafner M and Rudolf R: A scaffold-free 3-D co-culture mimics the major features of the reverse warburg effect in vitro. Cells. 9:19002020. View Article : Google Scholar :
14	Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, et al: CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 18:912019. View Article : Google Scholar : PubMed/NCBI
15	Musa M and Ali A: Cancer-associated fibroblasts of colorectal cancer and their markers: Updates, challenges and translational outlook. Future Oncol. 16:2329–2344. 2020. View Article : Google Scholar : PubMed/NCBI
16	Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 17:1472018. View Article : Google Scholar : PubMed/NCBI
17	Kalluri R and LeBleu VS: The biology, function, and biomedical applications of exosomes. Science. 367:eaau69772020. View Article : Google Scholar :
18	Mao L, Li X, Gong S, Yuan H, Jiang Y, Huang W, Sun X and Dang X: Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis. Cancer Gene Ther. 25:248–259. 2018. View Article : Google Scholar : PubMed/NCBI
19	Chaput N and Théry C: Exosomes: Immune properties and potential clinical implementations. Semin Immunopathol. 33:419–440. 2011. View Article : Google Scholar
20	Kahlert C and Kalluri R: Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 91:431–437. 2013. View Article : Google Scholar
21	Wang H, Wei H, Wang J, Li L, Chen A and Li Z: MicroRNA-181d-5p-containing exosomes derived from CAFs promote EMT by regulating CDX2/HOXA5 in breast cancer. Mol Ther Nucleic Acids. 19:654–667. 2020. View Article : Google Scholar : PubMed/NCBI
22	Wei H, Wang J, Xu Z, Li W, Wu X, Zhuo C, Lu Y, Long X, Tang Q and Pu J: Hepatoma cell-derived extracellular vesicles promote liver cancer metastasis by inducing the differentiation of bone marrow stem cells through microRNA-181d-5p and the FAK/Src pathway. Front Cell Dev Biol. 9:6070012021. View Article : Google Scholar : PubMed/NCBI
23	Huang H, Weng H and Chen J: The biogenesis and precise control of RNA m⁶A methylation. Trends Genet. 36:44–52. 2020. View Article : Google Scholar
24	Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, Yuan W, Kan Q and Sun Z: The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 12:1212019. View Article : Google Scholar : PubMed/NCBI
25	Kobayashi M, Ohsugi M, Sasako T, Awazawa M, Umehara T, Iwane A, Kobayashi N, Okazaki Y, Kubota N, Suzuki R, et al: The RNA methyltransferase complex of WTAP, METTL3, and METTL14 regulates mitotic clonal expansion in adipogenesis. Mol Cell Biol. 38:e00116–18. 2018. View Article : Google Scholar : PubMed/NCBI
26	Liu X, Liu L, Dong Z, Li J, Yu Y, Chen X, Ren F, Cui G and Sun R: Expression patterns and prognostic value of m⁶A-related genes in colorectal cancer. Am J Transl Res. 11:3972–3991. 2019.
27	Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, Li S, Tan L, Mai D, Li G, et al: Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 10:18582019. View Article : Google Scholar :
28	Dang TL, Le CT, Le MN, Nguyen TD, Nguyen TL, Bao S, Li S and Nguyen TA: Select amino acids in DGCR8 are essential for the UGU-pri-miRNA interaction and processing. Commun Biol. 3:3442020. View Article : Google Scholar : PubMed/NCBI
29	Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QG, Zhou WP and Sun SH: METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶-methyladenosine-dependent primary MicroRNA processing. Hepatology. 65:529–543. 2017. View Article : Google Scholar
30	Alarcón CR, Lee H, Goodarzi H, Halberg N and Tavazoie SF: N6-methyladenosine marks primary microRNAs for processing. Nature. 519:482–485. 2015. View Article : Google Scholar : PubMed/NCBI
31	Yasuda T, Koiwa M, Yonemura A, Akiyama T, Baba H and Ishimoto T: Protocol to establish cancer-associated fibroblasts from surgically resected tissues and generate senescent fibroblasts. STAR Protoc. 2:1005532021. View Article : Google Scholar : PubMed/NCBI
32	Yu S, Xia S, Yang D, Wang K, Yeh S, Gao Z and Chang C: Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion. Med Oncol. 30:6742013. View Article : Google Scholar : PubMed/NCBI
33	Kashima H, Wu RC, Wang Y, Sinno AK, Miyamoto T, Shiozawa T, Wang TL, Fader AN and Shih IeM: Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gynecol Oncol. 139:338–344. 2015. View Article : Google Scholar : PubMed/NCBI
34	Xiong S, Zheng Y, Jiang P, Liu R, Liu X and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 7:805–814. 2011. View Article : Google Scholar : PubMed/NCBI
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
36	Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J, Liu X, Chen CH, Fadare O, Pizzo DP, et al: Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 20:597–609. 2018. View Article : Google Scholar : PubMed/NCBI
37	Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, et al: Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing β1 integrin, enhancing drug resistance. Cancer Res. 80:3222–3235. 2020. View Article : Google Scholar : PubMed/NCBI
38	Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C, Prado-Lourenco L, Levin MG, Thacker S, et al: HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. 5:32922014. View Article : Google Scholar : PubMed/NCBI
39	Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 13:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
40	Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE and Mirnezami AH: Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett. 420:228–235. 2018. View Article : Google Scholar : PubMed/NCBI
41	Zhang Y, Geng X, Li Q, Xu J, Tan Y, Xiao M, Song J, Liu F, Fang C and Wang H: m6A modification in RNA: Biogenesis, functions and roles in gliomas. J Exp Clin Cancer Res. 39:1922020. View Article : Google Scholar : PubMed/NCBI
42	Chen XY, Zhang J and Zhu JS: The role of m⁶A RNA methylation in human cancer. Mol Cancer. 18:1032019. View Article : Google Scholar
43	Deng X, Su R, Weng H, Huang H, Li Z and Chen J: RNA N⁶-methyladenosine modification in cancers: Current status and perspectives. Cell Res. 28:507–517. 2018. View Article : Google Scholar : PubMed/NCBI
44	Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, Zhang X, Cao Y, Ma D, Zhu X, et al: m⁶A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 19:722020. View Article : Google Scholar
45	Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, et al: m⁶A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 20:1074–1083. 2018. View Article : Google Scholar : PubMed/NCBI
46	Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gong Z, Wang Q, Huang J, Tang C, et al: Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 534:575–578. 2016. View Article : Google Scholar : PubMed/NCBI
47	Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor progression via an m⁶A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 18:1122019. View Article : Google Scholar
48	Wang H, Xu B and Shi J: N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene. 722:1440762020. View Article : Google Scholar
49	O'Brien J, Hayder H, Zayed Y and Peng C: Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 9:4022018. View Article : Google Scholar
50	Peng Y and Croce CM: The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1:150042016. View Article : Google Scholar : PubMed/NCBI
51	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
52	Sun S, Hang T, Zhang B, Zhu L, Wu Y, Lv X, Huang Q and Yao H: miRNA-708 functions as a tumor suppressor in colorectal cancer by targeting ZEB1 through Akt/mTOR signaling pathway. Am J Transl Res. 11:5338–5356. 2019.PubMed/NCBI
53	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar
54	Denli AM, Tops BB, Plasterk RH, Ketting RF and Hannon GJ: Processing of primary microRNAs by the microprocessor complex. Nature. 432:231–235. 2004. View Article : Google Scholar : PubMed/NCBI
55	Guo Y, Tian P, Yang C, Liang Z, Li M, Sims M, Lu L, Zhang Z, Li H, Pfeffer LM and Yue J: Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion. Pharm Res. 32:769–778. 2015. View Article : Google Scholar : PubMed/NCBI
56	Gao LM, Zheng Y, Wang P, Zheng L, Zhang WL, Di Y, Chen LL, Yin XB, Tian Q, Shi SS and Xu SF: Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro. Am J Physiol Lung Cell Mol Physiol. 316:L918–L933. 2019. View Article : Google Scholar : PubMed/NCBI
57	Huang L, Wen C, Yang X, Lou Q, Wang X, Che J, Chen J, Yang Z, Wu X, Huang M, et al: PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. Cell Death Dis. 9:2712018. View Article : Google Scholar : PubMed/NCBI
58	Feng LY and Li L: Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer. J Ovarian Res. 13:352020. View Article : Google Scholar : PubMed/NCBI
59	Dong C, Yin F, Zhu D, Cai X, Chen C and Liu X: NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer. J Cell Biochem. 121:4470–4483. 2020. View Article : Google Scholar : PubMed/NCBI
60	Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al: A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 20:174–186. 2020. View Article : Google Scholar : PubMed/NCBI